S. J. Forman

This study develops TAG72-CAR T cells with antigen-dependent IL-12 signaling to enhance anti-tumor activity and systemic disease targeting in ovarian cancer.

This study compares IL13-ligand CAR designs to determine how co-stimulation domains affect tumor selectivity and anti-tumor activity against glioblastoma.

This study shows that PD-L1 blockade enhances CAR T cell activity by altering macrophage phenotypes through IFNγ signaling in the tumor microenvironment.

This study shows that cyclophosphamide pre-conditioning improves CAR T cell efficacy against solid tumors by modifying the immunosuppressive tumor microenvironment without harming normal tissues.

This study develops a CAR T cell therapy using chlorotoxin to target glioblastoma with high specificity and potency, overcoming tumor heterogeneity challenges.

This study shows that daratumumab targets CD38+ NK cells to induce immune activation and anti-myeloma activity despite reducing total NK cell frequency.

This study combines oncolytic viruses with CAR T cells to deliver CD19 antigen to solid tumors, enhancing CAR T cell anti-tumor responses.